他汀类宿主导向辅助治疗改善小鼠结核相关结局
该研究在体外和两种小鼠模型中筛选8种他汀作为一线抗结核药的辅助治疗。普伐他汀细胞毒性最低,可调节巨噬细胞吞噬体成熟,并在标准化疗模型和类人坏死性肉芽肿模型中显示强效辅助活性。数据支持普伐他汀作为结核宿主导向辅助治疗进入临床评估。
要点
- 普伐他汀在THP-1和Vero细胞中毒性最低。
- 辛伐他汀、氟伐他汀和普伐他汀增强一线药抗结核活性。
- 普伐他汀在两种小鼠结核模型中显示辅助活性。
核心结论
- 数据支持普伐他汀作为结核辅助宿主导向治疗进行临床评估。
研究设计与样本
- 筛选8种市售他汀的细胞毒性、抗结核活性、与一线药协同、药代动力学和辅助杀菌活性。
- 在两种不同小鼠模型中评估他汀作为一线结核药的辅助治疗。
主要发现
- 普伐他汀在THP-1和Vero细胞中显示最低毒性。
- 在非毒性剂量下,阿托伐他汀和美伐他汀不能抑制THP-1细胞中Mtb生长。
- 辛伐他汀、氟伐他汀和普伐他汀治疗指数最有利,并增强异烟肼、利福平和吡嗪酰胺在THP-1细胞中的抗结核活性。
- 普伐他汀调节巨噬细胞吞噬体成熟特征,模拟巨噬细胞活化,并在标准小鼠结核化疗模型和类人坏死性结核肺肉芽肿模型中显示强效辅助活性。
临床怎么用
- 普伐他汀有潜力作为结核一线化疗的辅助宿主导向治疗,但需临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) treatment is lengthy and complicated and patients often develop chronic lung disease. Recent attention has focused on host-directed therapies aimed at optimizing immune responses to Mycobacterium tuberculosis (Mtb), as adjunctive treatment given with antitubercular drugs. In addition to their cholesterol-lowering properties, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have broad anti-inflammatory and immunomodulatory activities. METHODS: In the current study, we screened 8 commercially available statins for cytotoxic effect, anti-TB activity, synergy with first-line drugs in macrophages, pharmacokinetics and adjunctive bactericidal activity, and, in 2 different mouse models, as adjunctive therapy to first-line TB drugs. RESULTS: Pravastatin showed the least toxicity in THP-1 and Vero cells. At nontoxic doses, atorvastatin and mevastatin were unable to inhibit Mtb growth in THP-1 cells. Simvastatin, fluvastatin, and pravastatin showed the most favorable therapeutic index and enhanced the antitubercular activity of the first-line drugs isoniazid, rifampin, and pyrazinamide in THP-1 cells. Pravastatin modulated phagosomal maturation characteristics in macrophages, phenocopying macrophage activation, and exhibited potent adjunctive activity in the standard mouse model of TB chemotherapy and in a mouse model of human-like necrotic TB lung granulomas. CONCLUSIONS: These data provide compelling evidence for clinical evaluation of pravastatin as adjunctive, host-directed therapy for TB.
引用
- Dutta NK, Bruiners N, Zimmerman MD, et al. Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice. J Infect Dis. 2020. PMID: 31605489. doi:10.1093/infdis/jiz517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。